Asiye PEREK, Sadık PEREK, Kemal ŞARMAN, Erenler İlknur KILIÇ, A. Ahad ANDİCAN

Duodenal stromal tümör

Duodenum tümörleri sık değildir ve benign tümörleri daha da az görülmektedir. Tüm gastrointestinal stromal tümörlerin % 20-30’u ince barsaktadır ve yaklaşık üçde biri duodenumdan kaynaklanmaktadır. En sık başvuru nedenleri gastrointestinal kanama, karında kitle ve ağrıdır. İmmünohistokimyasal çalışmalar tanıda ve bu tümörlerin ayırıcı tanısında önemlidir. CD34 ve CD 117 pozitifdir. Biz burada melena ile başvuran, duodenum ikinci ve üçüncü kıtası arasında yerleşen gastrointestinal stromal tümör tespit edilen ve wedge rezeksiyon yapılıp primer kapatılan bir olguyu sunduk.

Duodenal stromal tumor

Tumors of the duodenum are uncommon, and benign tumors are much rare. Overall 20-30% of gastrointestinal stromal tumors occur in the small bowel and about one third of these arise in the duodenum. The most common presentation is upper gastrointestinal bleeding, abdominal mass and pain. Immunohistochemical analysis is important in the diagnosis and differantial diagnosis of these tumors. They express CD 34 and CD 117 positivity. Here we report the case of a patient who applied with melena, that was diagnosed as due to the gastrointestinal stromal tumor located between the second and third portion of the duodenum, and managed by wedge resection and primary suture.

PDF

___

1. Yao KA, Talamati MS, Langella RL, Schindler NM, Rao S, Small W Jr, Johel RJ. Primary gastrointestinal sarcomas: analysis of prognostic factors and result of surgical management. Surgery 2000; 128: 604-612.
2. Wang L, Vargas H, French SW. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases. Arch Pathol Lab Med 2000; 124: 1471-1475.
3. De Matteo RP, Lewis JJ, Leung D. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
4. Hirota S, Isozaki K, Moriyama Y, hashimoto K, Nishida T, Ishigura S, Kiyoshi K, et al.. Gain of function mutations of c-kit in human gastrointestinal stromal tumor. Science 1998; 279: 577-580.
5. Shidham VB, Chivukula M, Gupta D, Rao RN, Komorowski K. Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med 2002; 126: 1189-1192.
6. Miettinen M, Kopczynski J, Makhlouf HR, Sarloma-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical and molecular genetic study of 167 cases. Am J Surg Pathol 2003;27: 625-641.
7. Montgomery E, Torbenson MS, Kaushal M, Fisher C, Abraham SC. Beta-Catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 2002; 26: 1296-1301.
8. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD ll7: a sensetive marker for gastrointestinal stromal tumors that is more specific than CD 34. Mod Pathol 1998; 11: 728-734.
9. Gunawan B, Bergmann F, Hoer J, Langer C, Schumpelick V, Becker H, Fuzesi L. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 2002; 33: 316-321.
10. Mori T, Hamada Y, Kamano N, Sakaida N, Okamura A, Hioki K. A case of gastrointestinal stromal tumor of duodenum diagnosed before operation. Jpn J Gastroenterol Surg 2000; 33: 333-337.
11. Perego M, Strada E, Alvisi C, Ascari E. Gastrointestinal stromal tumor as the cause of intestinal hemorrhage: description of a clinical case. Ann Ital Med Int 1998;13: 125-127.
12. Fletcher CDM, Berman JJ, Corless C, gorstein F, Lasota J, Longley J, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-465.
13. Miettinen M, El_Rifai W, HL Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal tumors: a review. Hum pathol 2002; 338: 478-483.
14. Patel SR, Benjamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surgical Oncology 2000; 9: 67-70.
15. Kim CJ, Day S, Yeh KA..Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am Surg 2001; 67: 135-137.
16. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal tumors before and after STI-571. Hum Pathol 2002; 33: 466-477.
17. Berman J, O’Leary TJ. Prospectives in pathology. Gastrointestinal stromal tumor workshop. Human Pathol 2001; 32: 578-582.
18. Tsukuda K, Hirai R, Miyake T, Takagi S, Ikeda E, Kunitomo T, Tsuji H. The Outcome of Gastrointestinal Stromal Tumors (GISTs) After a Surgical Resection in Our Institute. The Outcome of Gastrointestinal Stromal Tumors (GISTs) After a Surgical Resection in Our Institute. Surg Today 2007; 37: 953-957.
19. Kwon SH, Cha HJ, Jung SW, Kim BC, Park JS, Jeong ID, Lee JH, Nah YW, Bang SJ, Shin JW, Park NH, Kim DH. A gastrointestinal stromal tumor of the duodenum masquerading as a pancreatic head tumor. World J Gastroenterol 2007; 13: 3396-3399.
20.Weber AG, Jovenin N, Lubrano D, Journu J, Yaziji N, Bouche O, Diebold MD, Delattre JF. Outcome after surgical treatment of gastrointestinal stromal tumors. Gastroenterol Clin Biol 2007; 31: 579-584.